Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 6, Issue 2, 2001, Pages 175-181

  Sun, Yi Ping ^a   Zhu, Bo Qing ^a   Browne, Amanda E M ^a   Pulukurthy, Satyavardhan ^a   Chou, Tony M ^a   Sudhir, Krishnankutty ^b   Glantz, Stanton A ^a   Deedwania, Prakash C ^a   Chatterjee, Kanu ^a   Parmley, William W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Atherosclerosis; Vascular function

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KININ; LIPID; LOSARTAN; NITRIC OXIDE; QUINAPRIL; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; CHOLESTEROL DIET; CONCENTRATION RESPONSE; CONTROLLED STUDY; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; VASCULAR ENDOTHELIUM; VASODILATATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIOSCLEROSIS; CAPTOPRIL; CHOLESTEROL; DISEASE MODELS, ANIMAL; ISOQUINOLINES; KININS; LOSARTAN; MALE; NITRIC OXIDE; RABBITS; RECEPTORS, ANGIOTENSIN; TETRAHYDROISOQUINOLINES; VASOCONSTRICTION; VASODILATION;

EID: 0034762577     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840100600209     Document Type: Article

References (39)

1. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis
2. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: A novel autocrine function
3. Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits
4. Angiotensin, LDL peroxidation and atherosclerosis
5. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo
6. Quantitative determination of serum triglycerides by the use of enzymes
7. Enzymatic determination of total serum cholesterol
8. Quantification of high-density-lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2
9. Analysis of plasma lipoproteins by ultracentrifugation in a new fixed angle rotor: Evaluation of a phosphotungstic acid/MgCl2 precipitation and a quantitative lipoprotein electrophoresis assay
10. Interference of eluates from octadecyl cartridges with an angiotensin II radioimmunoassay
11. Role of endogenous angiotensin II in the control of vasopressin secretion during hypovolemia and hypotension in conscious rabbits
12. Arginine restores nitric oxide activity and inhibits monocyte accumulation after vascular injury in hypercholesterolemic rabbits
13. In-utero and neonatal exposure to secondhand smoke causes vascular dysfunction in newborn rats
14. Aspirin inhibits platelet activity but does not attenuate experimental atherosclerosis
15. Passive smoking increases experimental atherosclerosis in cholesterol-fed rabbits
16. Effects of antioxidant vitamins C and E on atherosclerosis in lipid-fed rabbits
17. Angiotensin II induces apoptosis of human endothelial cells. Protective effect of nitric oxide
18. Rationale and pharmacology of angiotensin II receptor antagonists: Current status and future issues
19. ACE inhibition with perindopril and atherogenesis-induced structural and functional changes in minipig arteries
20. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury
21. Influence of tissue affinity of angiotensin-converting enzyme inhibitors on left ventricular remodeling after myocardial infarction
22. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF Study)
23. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
24. Losartan in heart failure: Preclinical experiences and initial clinical outcomes
25. Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells
26. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia
27. Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, losartan
28. Randomized trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE)
29. Local regulation of vascular tone by bradykinin and angiotensin converting enzyme inhibitors
30. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure
31. Distribution and function of angiotensin receptor subtypes in cardiovascular system. Nippon Rinsho
32. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells
33. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism
34. Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery
35. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats
36. Renal actions of angiotensin-(1-7): In vivo and in vitro studies
37. Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats
38. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors
39. AT1 receptor blockade in experimental myocardial ischemia/reperfusion